Arovella Therapeutics Ltd

ALA

Company Profile

  • Business description

    Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

  • Contact

    84 Hotham Street
    Corporate One
    PrestonVIC3072
    AUS

    T: +61 398636472

    https://www.arovella.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    44

Stocks News & Analysis

stocks

Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown

We think Amazon stock looks attractive.
stocks

Apple earnings: Strong iPhone beat brings our valuation up and tariff costs prove light for now

We think Apple stock looks fairly valued.
stocks

4 ASX shares that could be vulnerable to an August surprise

Any missteps this reporting season could be costly for these shares, which have all risen to lofty valuations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,900.7016.40-0.18%
CAC 407,546.16225.81-2.91%
DAX 4023,425.97639.50-2.66%
Dow JONES (US)43,588.58542.40-1.23%
FTSE 1009,068.5864.23-0.70%
HKSE24,507.81265.52-1.07%
NASDAQ20,650.13472.31-2.24%
Nikkei 22539,949.12850.48-2.08%
NZX 50 Index12,734.535.130.04%
S&P 5006,238.01101.38-1.60%
S&P/ASX 2008,646.3015.70-0.18%
SSE Composite Index3,559.9513.26-0.37%

Market Movers